Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Rossi E, Donzelli C, Todeschini P, Romani C, Bandiera E, Zanotti L, Carnazza M, Quadraro F, Tognon G, Sartori E, Pecorelli S, Roque DM, Santin AD.

J Transl Med. 2013 Jul 2;11:162. doi: 10.1186/1479-5876-11-162.

2.
3.

Differential expression of secretoglobins in normal ovary and in ovarian carcinoma--overexpression of mammaglobin-1 is linked to tumor progression.

Fischer K, von Brünneck AC, Hornung D, Denkert C, Ufer C, Schiebel H, Kuhn H, Borchert A.

Arch Biochem Biophys. 2014 Apr 1;547:27-36. doi: 10.1016/j.abb.2014.02.012. Epub 2014 Mar 3.

PMID:
24603286
4.

Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence.

Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, Romani C, Bandiera E, Zanotti L, Pecorelli S, Santin AD.

BMC Cancer. 2009 Jul 27;9:253. doi: 10.1186/1471-2407-9-253.

5.

Mammaglobin and lipophilin B expression in breast tumors and their lack of effect on breast cancer cell proliferation.

Sjödin A, Ljuslinder I, Henriksson R, Hedman H.

Anticancer Res. 2008 May-Jun;28(3A):1493-8.

6.

Overexpression of mammaglobin B in epithelial ovarian carcinomas.

Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD.

Gynecol Oncol. 2007 Jun;105(3):578-85. Epub 2007 Mar 6.

PMID:
17343903
7.

Secretoglobins in the human pituitary: high expression of lipophilin B and its down-regulation in pituitary adenomas.

Sjödin A, Guo D, Lund-Johansen M, Krossnes BK, Lilleng P, Henriksson R, Hedman H.

Acta Neuropathol. 2005 Apr;109(4):381-6. Epub 2005 Jan 25.

PMID:
15668787
8.

Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients.

Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD.

Eur J Cancer. 2010 Mar;46(5):944-53. doi: 10.1016/j.ejca.2009.12.019. Epub 2010 Jan 8.

PMID:
20060709
9.

DEF6 expression in ovarian carcinoma correlates with poor patient survival.

Liew PL, Fang CY, Lee YC, Lee YC, Chen CL, Chu JS.

Diagn Pathol. 2016 Aug 3;11(1):68. doi: 10.1186/s13000-016-0518-y.

10.

Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer.

Culleton J, O'Brien N, Ryan BM, Hill AD, McDermott E, O'Higgins N, Duffy MJ.

Int J Cancer. 2007 Mar 1;120(5):1087-92.

11.

The potential prognostic value of cathepsin D protein in serous ovarian cancer.

Chai Y, Wu W, Zhou C, Zhou J.

Arch Gynecol Obstet. 2012 Aug;286(2):465-71. doi: 10.1007/s00404-012-2318-2. Epub 2012 Apr 3.

PMID:
22476353
12.

Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma.

Guo X, Xiong L, Sun T, Peng R, Zou L, Zhu H, Zhang J, Li H, Zhao J.

Diagn Pathol. 2012 Apr 19;7:44. doi: 10.1186/1746-1596-7-44.

13.

LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors.

Yin M, Lou C, Zhang W, Meng F, Zhang H, Ning X, Zhou R, Dong X, Lou G.

Int J Gynecol Cancer. 2012 Jan;22(1):54-62. doi: 10.1097/IGC.0b013e318234f9ac.

PMID:
22193644
14.

Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma.

Borgoño CA, Fracchioli S, Yousef GM, Rigault de la Longrais IA, Luo LY, Soosaipillai A, Puopolo M, Grass L, Scorilas A, Diamandis EP, Katsaros D.

Int J Cancer. 2003 Sep 10;106(4):605-10.

15.

[Expression and clinical significance of ELOVL6 gene in high-grade serous ovarian carcinoma].

Li FJ, Wang HY, Feng XL, Li PP, Shu T, Zhao XH, Li B.

Zhonghua Fu Chan Ke Za Zhi. 2016 Mar;51(3):192-7. doi: 10.3760/cma.j.issn.0529-567X.2016.03.006. Chinese.

PMID:
27030498
16.

Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer.

Li YL, Ye F, Cheng XD, Hu Y, Zhou CY, Lü WG, Xie X.

Eur J Cancer. 2010 Jul;46(11):2104-18. doi: 10.1016/j.ejca.2010.04.015. Epub 2010 May 22.

PMID:
20547056
17.

Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.

Denkert C, Weichert W, Pest S, Koch I, Licht D, Köbel M, Reles A, Sehouli J, Dietel M, Hauptmann S.

Cancer Res. 2004 Jan 1;64(1):189-95.

18.

The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.

Zhao Y, Zheng HC, Chen S, Gou WF, Xiao LJ, Niu ZF.

Gynecol Oncol. 2013 Sep;130(3):570-8. doi: 10.1016/j.ygyno.2013.06.004. Epub 2013 Jun 10.

PMID:
23764197
19.

Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.

Espinosa I, Catasus L, Canet B, D'Angelo E, Muñoz J, Prat J.

Mod Pathol. 2011 Jun;24(6):846-54. doi: 10.1038/modpathol.2011.12. Epub 2011 Feb 11.

20.

Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer.

Leoutsakou T, Talieri M, Scorilas A.

Biochem Biophys Res Commun. 2006 Jun 2;344(2):667-74. Epub 2006 Apr 7.

PMID:
16631123

Supplemental Content

Support Center